Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Severe Hemophilia A

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

December 25, 2026

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Severe Hemophilia A
Interventions
DRUG

FRSW107

experimental:Q3D.≥50EDs, Expansion phase:Q3D.100EDs

Trial Locations (13)

Unknown

Children's Hospital Affiliated to Chongqing Medical University, Chongqing

Guangzhou Women and Children Medical Center, Guangzhou

Nanfang Hospital, Southern Medical University, Guangzhou

Affiliated Hospital of Guizhou Medical University, Guizhou

Children's Hospital, Zhejiang University School of Medicine, Hangzhou

Anhui Children's Hospital, Hefei

The Second Affiliated Hospital of Anhui Medical University, Hefei

Nanjing Children's Hospital, Nanjing

Affiliated Hospital of Qingdao University, Qingdao

Shenzhen Children's Hospital, Shenzhen

Shanxi Children's Hospital, Taiyuan

Beijing Children's Hospital Affiliated to Capital Medical University, Tianjing

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

All Listed Sponsors
lead

Jiangsu Gensciences lnc.

INDUSTRY